Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

theoptionscoach Nov. 20 at 9:53 PM

$DJI $SPY $QQQ $WMT $JNJ Hello from theoptionscoach.net https://theoptionscoach.net/p/big-red-day

0 · Reply

Peaceouty Nov. 20 at 8:53 PM

$CANF $JNJ $QQQ $SPY $XBI No worries ✌🏻

0 · Reply

MoneyGroupLLC Nov. 20 at 8:45 PM

Enter: $JNJ Calls Strike Price: $205 Expiry Date: DEC 12 2025 Buy in Price: $2.77 - $2.78 Sell Price: $5.90 Profit : +113% (Turn every $1 into $2.13) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

catherineWlkr08 Nov. 20 at 8:37 PM

$JNJ

0 · Reply

Bull_sheet Nov. 20 at 8:26 PM

$JNJ one of the few stocks that’s isn’t dumping

0 · Reply

Stocktrader3546 Nov. 20 at 8:25 PM

$JNJ what the fuck is wrong with the bulls on this..keeps dragging up

0 · Reply

traderjoe90 Nov. 20 at 7:40 PM

$JNJ playa layin wood in Jun & Jul 185 calls. $7.1M

0 · Reply

LiquidThetaOptions Nov. 20 at 7:31 PM

💎 LiquidTheta® Live Actionable Trade Asset: $JNJ Contracts: $JNJ December 18, 2026 $210 Calls Scale in: $13.24- $16.18 Scale out: $51.48-$88.26 Profit Potential : 163% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Trader_Ty Nov. 20 at 6:55 PM

$JNJ I did not buy any LEAPs. wah wah

0 · Reply

JustChillTrader Nov. 20 at 6:53 PM

$JNJ with tomorrow earnings, any predictions

1 · Reply

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN LLY MDT MRK NVO OLMA PFE

Nov 18, 2025, 8:25 AM EST - 2 days ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD GSK LLY

Nov 17, 2025, 6:07 PM EST - 2 days ago

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Nov 17, 2025, 1:17 PM EST - 3 days ago

Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 17, 2025, 8:29 AM EST - 3 days ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:15 AM EST - 3 days ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:07 AM EST - 3 days ago

J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion

Nov 17, 2025, 8:05 AM EST - 3 days ago

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Nov 17, 2025, 8:00 AM EST - 3 days ago

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics

Nov 14, 2025, 3:19 PM EST - 6 days ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

ABBV AZN LLY MRK NVO PFE XLV

Nov 14, 2025, 8:03 AM EST - 6 days ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY

Nov 11, 2025, 1:41 PM EST - 9 days ago

Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 12:51 PM EST - 9 days ago

Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 10, 2025, 6:26 AM EST - 10 days ago

Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating

Nov 7, 2025, 12:57 PM EST - 13 days ago

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

Nov 7, 2025, 5:40 AM EST - 13 days ago

Johnson & Johnson: Dividends Don't Lie

Nov 6, 2025, 5:07 PM EST - 14 days ago

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

Nov 6, 2025, 9:54 AM EST - 14 days ago

Cramer's Mad Dash: Johnson & Johnson

Nov 6, 2025, 7:34 AM EST - 14 days ago

US FDA expands use of J&J's Caplyta as add-on depression drug

Nov 6, 2025, 7:30 AM EST - 14 days ago

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

Nov 5, 2025, 4:50 PM EST - 15 days ago

Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference

Nov 1, 2025, 10:25 AM EDT - 19 days ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO

Oct 29, 2025, 8:05 AM EDT - 22 days ago

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Oct 29, 2025, 5:11 AM EDT - 22 days ago

Best Dividend Kings: October 2025

ABBV ABM ABT ADM ADP AWR BDX

Oct 28, 2025, 6:15 PM EDT - 23 days ago

Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson

Oct 28, 2025, 9:25 AM EDT - 23 days ago

J&J Stock Can Fall

Oct 28, 2025, 9:13 AM EDT - 23 days ago

Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks

KVUE

Oct 27, 2025, 8:00 AM EDT - 24 days ago

New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

Oct 27, 2025, 7:30 AM EDT - 24 days ago

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

Oct 27, 2025, 7:30 AM EDT - 24 days ago

Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis

Oct 24, 2025, 6:32 PM EDT - 27 days ago

Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies

Oct 24, 2025, 8:00 AM EDT - 27 days ago

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis

Oct 24, 2025, 4:30 AM EDT - 27 days ago

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

APD CNC COF FISV IQV IVZ LRCX

Oct 23, 2025, 10:52 AM EDT - 4 weeks ago

These low-risk stocks could be a profitable answer to this volatile earnings season

AMGN BMY CVS GD GIS HQY HRL

Oct 22, 2025, 4:36 PM EDT - 4 weeks ago

Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference

Oct 22, 2025, 2:00 PM EDT - 4 weeks ago

Johnson & Johnson Stock To $134?

Oct 19, 2025, 10:30 AM EDT - 4 weeks ago

Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Oct 16, 2025, 8:00 AM EDT - 5 weeks ago

TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

Oct 15, 2025, 7:03 PM EDT - 5 weeks ago

J&J faces first UK lawsuits alleging its baby powder caused cancer

Oct 15, 2025, 2:04 PM EDT - 5 weeks ago

These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings

Oct 15, 2025, 1:56 PM EDT - 5 weeks ago

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

Oct 15, 2025, 7:51 AM EDT - 5 weeks ago

Johnson & Johnson reveals 2025 sales forecast and plans for its orthopedics business

Oct 14, 2025, 7:30 PM EDT - 5 weeks ago

'NEVER BEEN STRONGER': Johnson & Johnson leader touts latest innovations

Oct 14, 2025, 12:36 PM EDT - 5 weeks ago

Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript

Oct 14, 2025, 10:01 AM EDT - 5 weeks ago

Citi (C) Posts Strong Earnings, Stuffed Crust Strengthens DPZ, JNJ Slides

C DPZ

Oct 14, 2025, 8:58 AM EDT - 5 weeks ago

Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again

Oct 14, 2025, 8:56 AM EDT - 5 weeks ago

Johnson & Johnson to spin off orthopedics unit after raising 2025 sales forecast

Oct 14, 2025, 8:51 AM EDT - 5 weeks ago

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook

Oct 14, 2025, 7:44 AM EDT - 5 weeks ago

Johnson & Johnson's stock heads for a record after a profit beat and plans for another spinoff

Oct 14, 2025, 7:33 AM EDT - 5 weeks ago

J&J CEO Joaquin Duato on Q3 results: We are entering an era of accelerated growth

theoptionscoach Nov. 20 at 9:53 PM

$DJI $SPY $QQQ $WMT $JNJ Hello from theoptionscoach.net https://theoptionscoach.net/p/big-red-day

0 · Reply

Peaceouty Nov. 20 at 8:53 PM

$CANF $JNJ $QQQ $SPY $XBI No worries ✌🏻

0 · Reply

MoneyGroupLLC Nov. 20 at 8:45 PM

0 · Reply

catherineWlkr08 Nov. 20 at 8:37 PM

$JNJ

0 · Reply

Bull_sheet Nov. 20 at 8:26 PM

$JNJ one of the few stocks that’s isn’t dumping

0 · Reply

Stocktrader3546 Nov. 20 at 8:25 PM

$JNJ what the fuck is wrong with the bulls on this..keeps dragging up

0 · Reply

traderjoe90 Nov. 20 at 7:40 PM

$JNJ playa layin wood in Jun & Jul 185 calls. $7.1M

0 · Reply

LiquidThetaOptions Nov. 20 at 7:31 PM

0 · Reply

Trader_Ty Nov. 20 at 6:55 PM

$JNJ I did not buy any LEAPs. wah wah

0 · Reply

JustChillTrader Nov. 20 at 6:53 PM

$JNJ with tomorrow earnings, any predictions

1 · Reply

Wallstfan Nov. 20 at 2:55 PM

$WMT $JNJ $TMUS $DUK $WM these are the only names I own right now. I still don’t trust these market. Recession is still on the table for 2026

0 · Reply

Quantumup Nov. 20 at 1:40 PM

Evercore ISI🏁 $ORIC Outperform/$25 $PFE $BAYRY - $ORINY $JNJ Evercore ISI in its initiation report said:

0 · Reply

SuperGreenToday Nov. 20 at 9:31 AM

$JNJ Share Price: $202.66 Contract Selected: Dec 12, 2025 $205 Calls Buy Zone: $2.12 – $2.62 Target Zone: $3.67 – $4.48 Potential Upside: 63% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

HedgeAlerts Nov. 20 at 7:30 AM

Hedge Alert Live - Protect Your Portfolio Contract: $JNJ $202.50 Put · NOV 28, 2025 Exp Entry Price: $2.65 - $2.78 Exit Price Target: $5.14 Profit Margin: +94% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Peaceouty Nov. 20 at 6:34 AM

$CANF Has more buns in the oven than you think! This’s a HUGE deal imo. Namodenoson is also currently being evaluated in a phase 3 liver cancer trial. FDA fast track and Orphan drug designation. 👊🏻 Company has a cash burn rate of 1M a month and a current market cap of 5 mill. Efficacy is basically already proven in the hard to treat cases. $SPY $XBI $QQQ $JNJ https://ca.finance.yahoo.com/news/fite-reports-h1-2025-financial-124700966.html

0 · Reply

bdrd Nov. 19 at 10:31 PM

$JNJ $210 next

0 · Reply

HedgeAlerts Nov. 19 at 9:17 PM

Hedge Alert Live - Protect Your Portfolio Contract: $JNJ $200.00 Put · NOV 28, 2025 Exp Entry Price: $1.70 - $2.08 Exit Price Target: $2.29 Profit Margin: +35% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Wenwenwenwenwenwen Nov. 19 at 9:01 PM

$JNJ aged well😊 now keep pumping…

0 · Reply

Iightning Nov. 19 at 8:47 PM

1ightning® Options Trade Alert (Actionable) | Buy $JNJ Dec 5 $200 Call | Enter: $2.82 Exit: $4.00 | Profit: 41.81% ROI | https://1ightning.com

0 · Reply

Wenwenwenwenwenwen Nov. 19 at 6:26 PM

$JNJ keep it pumping….harder…harder!

1 · Reply

RD008 Nov. 19 at 5:24 PM

$NVAX Somebody pls acquire NOVAVAX $JNJ $PFE

1 · Reply

Wenwenwenwenwenwen Nov. 19 at 4:47 PM

$JNJ whys this pumping?

1 · Reply

Market Cap	481.86B
Revenue (ttm)	88.82B
Net Income (ttm)	14.07B
EPS (ttm)	N/A
PE Ratio	18.88
Forward PE	18.03
Profit Margin	15.84%
Debt to Equity Ratio	0.50

Volume	10,602,971
Avg Vol	8,676,856
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	95%
Beta	0.38
Analysts	Strong Sell
Price Target	$203.50